在遗传代谢疾病中,肝脏基因转移用于代谢物解毒
Alfonso M D'Alessio1,2, Iolanda Boffa1,3, Lucia De Stefano1
1Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
FEBS letters
|June 17, 2024
概括
遗传代谢障碍 (IMD) 是影响细胞代谢的遗传性疾病. 本综述涵盖了针对IMD代谢物排毒的肝脏基因疗法方法,并讨论了当前的挑战.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 遗传代谢障碍 (IMD) 是由酶缺陷引起的遗传性疾病.
- 这些缺陷导致有毒物质的积累,影响细胞代谢.
- 肝脏是一个中心的代谢器官,经常受到IMD的影响.
研究的目的:
- 审查目前针对肝脏的基因治疗策略,以治疗IMD.
- 突出治疗方法专注于代谢物排毒.
- 讨论IMD基因疗法的现有挑战.
主要方法:
- 对IMD基因治疗的文献综述.
- 专注于针对肝脏新陈代谢的战略.
- 对当前治疗成功和局限性的分析.
主要成果:
- 基因疗法有潜力通过纠正代谢缺陷来治疗IMD.
- 由于肝脏的代谢作用,以肝脏为导向的方法至关重要.
- 虽然取得了重大进展,但仍然存在挑战.
结论:
- 以肝脏为导向的基因疗法是管理IMD的一个有希望的途径.
- 需要进一步的研究来克服有效性和安全性的挑战.
- 基因治疗的进步有可能改善IMD患者的治疗结果.
相关概念视频
Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drug Biotransformation: Overview
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Hepatic Drug Clearance: Role of Transporters
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...


